ClinicalTrials.gg
CompletedNCT04659161Updated Dec 12, 2023Results posted

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules and Placebo in Schizophrenia and Schizophrenia; Psychosis, sponsored by Karuna Therapeutics. Completed at 22 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-12.

Sponsored by Karuna Therapeutics (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
7th of 20
252 · median 178
Started
2020
the only one that year
Phase 3
14 of 20
4 open now
Registered
2nd of 20
by date
Lead sponsor
5 of 20
Karuna Therapeutics

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 14 in phase 3, and was the 2nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores in adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate improvement in disease severity and symptoms, safety and tolerability, and pharmacokinetics in adult inpatients with a DSM-5 diagnosis of schizophrenia.

03

Conditions studied

  • Schizophrenia
  • Schizophrenia; Psychosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged 18 to 65 years, inclusive, at screening.
  2. Subject is capable of providing .

    1. A signed informed consent form must be provided before any study assessments are performed.
    2. Subject must be fluent (oral and written) in English to consent
  3. Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI) version 7.0.2.
  4. Subject is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening.

    1. The subject requires hospitalization for this acute exacerbation or relapse of psychotic symptoms.
    2. If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening.
  5. Positive and Negative Syndrome Scale total score between 80 and 120, inclusive. Score of ≥4 (moderate or greater) for ≥2 of the following Positive Scale (P) items:

    1. Item 1 (P1; delusions)
    2. Item 2 (P2; conceptual disorganization)
    3. Item 3 (P3; hallucinatory behavior)
    4. Item 6 (P6; suspiciousness/persecution)
  6. Subjects with no change (improvement) in PANSS total score between screening and baseline (Day -1) of more than 20%.
  7. Subject has a CGI-S score of ≥4 at screening and baseline (Day -1) visits.
  8. Subject will have been off lithium therapy for at least 2 weeks before baseline and free of all oral antipsychotic medications for at least 5 half-lives or 1 week, whichever is longer, before baseline (Day -1).
  9. Subjects taking a long-acting injectable antipsychotic could not have received a dose of medication for at least 12 weeks (24 weeks for INVEGA TRINZA) before baseline visit (Day -1).
  10. Subject is willing and able to be confined to an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements.
  11. must be ≥18 and ≤40 kg/m2.
  12. Subject resides in a stable living situation and is anticipated to return to that same stable living situation after discharge, in the opinion of the investigator.
  13. Subject has an identified reliable informant.
  14. Women of , or men with sexual partners of childbearing potential, must be able and willing to use at least 1 highly effective method of during the study and for 30 days after the last dose of study drug. Sperm donation is not allowed for 30 days after the final dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Any primary disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening). Symptoms of mild mood dysphoria or anxiety are allowed as long as these symptoms are not the primary focus of treatment. A screening subject with mild substance abuse disorder within the 12 months before screening must be discussed and agreed upon with the medical monitor before they can be allowed into the study.
  2. Subjects who are newly diagnosed or are experiencing their first treated episode of schizophrenia.
  3. History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
  4. Subjects with , cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on either medical history or liver function test results.
  5. History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma.
  6. History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months.
  7. Risk for suicidal behavior during the study as determined by the investigator's clinical assessment and Columbia-Suicide Severity Rating Scale (C-SSRS).
  8. Clinically significant abnormal finding on the physical examination, medical history, , or clinical laboratory results at screening.
  9. Subjects cannot currently (within 5 half-lives or 1 week, whichever is longer, before baseline [Day -1]) be receiving oral antipsychotic medications; monoamine oxidase inhibitors; anticonvulsants (eg, lamotrigine, Depakote); tricyclic antidepressants (eg, imipramine, desipramine); selective serotonin reuptake inhibitors; or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam, chloral hydrate).
  10. Pregnant, lactating, or less than 3 months postpartum.
  11. If, in the opinion of the investigator (and/or Sponsor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the investigator (and/or Sponsor), may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements.
  12. Positive test for coronavirus (COVID-19) within 2 weeks before screening and at screening.
  13. Subjects with extreme concerns relating to global pandemics, such as COVID-19, that preclude study participation.
  14. Subject has had psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days before screening.
  15. Subject has a history of treatment resistance to schizophrenia medications defined as failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) or required clozapine within the last 12 months.
  16. Subjects with prior exposure to KarXT.
  17. Subjects who experienced any adverse effects due to xanomeline or trospium.
  18. Participation in another clinical study in which the subject received an experimental or drug agent within 3 months before screening.
  19. Risk of violent or destructive behavior.
  20. Current involuntary hospitalization or incarceration.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline and Trospium Chloride Capsules

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugXanomeline and Trospium Chloride Capsules

    Drug pages: Xanomeline · Trospium chloride

    Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.

    Also known as: KarXT

  • DrugPlacebo

    Placebo Capsules twice a day (BID)

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5

    The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. It takes approximately 45 to 50 minutes to administer. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline and Week 5

Secondary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5

    The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. For positive symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline and Week 5

  2. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5

    The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. For negative symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline and Week 5

  3. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Negative Score

    The Marder Factor Negative Score is derived from the Positive and Negative Syndrome Scale (PANSS) and consists of the sum of 5 negative scales (N) and 2 general scales (G) (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance), with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline and Week 5

  4. Change From Baseline Clinical Global Impression - Severity (CGI-S) Score at Week 5

    The CGI-S modified asked the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants.

    Time frame: Baseline and Week 5

  5. Percentage of Positive and Negative Syndrome Scale (PANSS) Responders (>=30% Change in PANSS Total Score) at Week 5

    The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A PANSS responder is defined as a participant with at least a 30% change in PANSS total score compared to baseline at Week 5.

    Time frame: Baseline and Week 5

07

Results

Posted Dec 12, 2023

Participant flow

The study was conducted in 21 study centers in the United States.

Participant flow — Overall Study
MilestoneKarXTPlacebo
Started126126
Completed94100
Not completed3226
Withdrew: Adverse event106
Withdrew: Withdrawal by subject1312
Withdrew: Other98

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5

The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. It takes approximately 45 to 50 minutes to administer. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5-21.2 ± 1.652-11.6 ± 1.600
Statistical analysis
  • KarXT vs Placebo · Mixed Model for Repeated Measures · p = <0.0001 · Ls mean difference: -9.6 · 95% CI -13.9 to -5.2
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5

The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. For positive symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5
score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5-6.8 ± 0.526-3.9 ± 0.512
Statistical analysis
  • KarXT vs Placebo · Mixed Model for Repeated Measures · p = <0.0001
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5

The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. For negative symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5
score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5-3.4 ± 0.479-1.6 ± 0.466
Statistical analysis
  • KarXT vs Placebo · Mixed Model Repeated Measures · p = 0.0055
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Negative Score

The Marder Factor Negative Score is derived from the Positive and Negative Syndrome Scale (PANSS) and consists of the sum of 5 negative scales (N) and 2 general scales (G) (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance), with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Negative Score
score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Negative Score-4.2 ± 0.530-2.0 ± 0.517
Statistical analysis
  • KarXT vs Placebo · Mixed Model for Repeated Measures · p = 0.0022
SecondaryChange From Baseline Clinical Global Impression - Severity (CGI-S) Score at Week 5

The CGI-S modified asked the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline Clinical Global Impression - Severity (CGI-S) Score at Week 5
score on a scaleKarXTPlacebo
Change From Baseline Clinical Global Impression - Severity (CGI-S) Score at Week 5-1.2 ± 0.103-0.7 ± 0.099
Statistical analysis
  • KarXT vs Placebo · Mixed Model for Repeated Measures · p = <0.0001
SecondaryPercentage of Positive and Negative Syndrome Scale (PANSS) Responders (>=30% Change in PANSS Total Score) at Week 5

The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A PANSS responder is defined as a participant with at least a 30% change in PANSS total score compared to baseline at Week 5.

Time frame:
Baseline and Week 5
Reported as:
Count of participants · Participants
Percentage of Positive and Negative Syndrome Scale (PANSS) Responders (>=30% Change in PANSS Total Score) at Week 5
ParticipantsKarXTPlacebo
Percentage of Positive and Negative Syndrome Scale (PANSS) Responders (>=30% Change in PANSS Total Score) at Week 55128
Statistical analysis
  • KarXT vs Placebo · Mixed Model for Repeated Measures · p = <0.0001

Adverse events

Collected over From the start of study drug administration up to Week 5.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KarXT0/126 (0%)2/126 (1.6%)95/126 (75.4%)
Placebo0/125 (0%)2/125 (1.6%)73/125 (58.4%)
Most frequent serious events
Most frequent serious events
EventKarXTPlacebo
Suicidal ideationPsychiatric disorders2/1260/125
AppendicitisInfections and infestations0/1261/125
SchizophreniaPsychiatric disorders0/1261/125
Most frequent other events
Showing 10 of 25
Most frequent other events
EventKarXTPlacebo
ConstipationGastrointestinal disorders27/12613/125
DyspepsiaGastrointestinal disorders24/12610/125
NauseaGastrointestinal disorders24/1267/125
VomitingGastrointestinal disorders18/1261/125
HeadacheNervous system disorders17/12615/125
HypertensionVascular disorders12/1261/125
DizzinessNervous system disorders11/1264/125
AgitationPsychiatric disorders2/1268/125
Gastrooesophageal reflux diseaseGastrointestinal disorders8/1260/125
Abdominal discomfortGastrointestinal disorders7/1264/125

Baseline characteristics

The Intent-to-Treat (ITT) population included all participants who were randomized to the study. Participants were analyzed according to randomized treatment.

Age, Continuous
Age, Continuous(years)KarXTPlaceboTotal
Mean45.6 ± 10.4246.2 ± 10.7845.9 ± 10.58
Sex: Female, Male
Sex: Female, Male(Participants)KarXTPlaceboTotal
Female313162
Male9595190
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)KarXTPlaceboTotal
Hispanic or Latino141125
Not Hispanic or Latino111114225
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)KarXTPlaceboTotal
Black or African American9792189
White263157
Asian213
Other123
Region of Enrollment
Region of Enrollment(participants)KarXTPlaceboTotal
United States126126252
Baseline PANSS Total Score
Baseline PANSS Total Score(units on a scale)KarXTPlaceboTotal
Mean98.3 ± 8.9397.9 ± 9.7198.1 ± 9.31
Baseline PANSS Positive Score
Baseline PANSS Positive Score(units on a scale)KarXTPlaceboTotal
Mean26.8 ± 3.7426.7 ± 3.9726.7 ± 3.85
Baseline PANSS Negative Score
Baseline PANSS Negative Score(units on a scale)KarXTPlaceboTotal
Mean22.9 ± 4.0022.9 ± 3.8222.9 ± 3.90

2 further baseline measures are reported on the registry.

08

Study locations

22 sites
  • Woodland International Research Group, LLC
    Little Rock, Arkansas 72211, United States
  • CITrials
    Bellflower, California 90706, United States
  • ProScience Research Institute
    Culver City, California 90230, United States
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • CNS Network
    Long Beach, California 90806, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • California Neuropsychopharmacology Clinical Research Institute
    Pico Rivera, California 90660, United States
  • California Neuropsychopharmacology Clinical Research Institute
    San Diego, California 92101, United States
  • Schuster Medical Research Institute
    Sherman Oaks, California 91403, United States
  • Innovative Clinical Research, Inc.
    Miami Lakes, Florida 33016, United States
  • Research Centers of America
    Oakland Park, Florida 33334, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Pillar Clinical Research
    Lincolnwood, Illinois 60712, United States
  • Arch Clinical Trials
    Saint Louis, Missouri 63118, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Neuro-Behavioral Clinical Research
    North Canton, Ohio 44720, United States
  • Community Clinical Research
    Austin, Texas 78754, United States
  • Pillar Clinical Research
    Richardson, Texas 75080, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in May 2022, 17 months.

Results were first posted in Dec 2023, 1 year 6 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 17 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 9, 2020
StartActual
Dec 16, 2020
Primary completionActual
May 24, 2022
CompletionActual
May 24, 2022
Results first posted
Dec 12, 2023
Last update
Dec 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04659161
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Dec 16, 2020
Primary completion
May 24, 2022
Completion
May 24, 2022
Results posted
Dec 12, 2023
Last update
Dec 12, 2023

Study contacts

Inder Kaul, MD
study director · Karuna Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion